• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (21)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Douglas A. Jabs, MD

Arch Ophthalmol. 1992;110(2):185-187.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Cytomegalovirus (CMV) retinitis is the most frequent opportunistic ocular infection in patients with the acquired immunodeficiency syndrome (AIDS),^1-6 and, when left untreated, ultimately leads to blindness.⁴ Approximately 20% of patients with AIDS develop CMV retinitis at some time in their lives.^1-5 With the advent of the AIDS epidemic,⁷ there may be as many as 20 000 to 30 000 new cases of CMV retinitis in the United States in 1992.

See also pp 188 and 255.

Two drugs have been approved for the treatment of CMV retinitis: ganciclovir (Cytovene, Syntex Laboratories Inc, Palo Alto, Calif)^4,6,8-13 and foscarnet (Foscavir, Astra Pharmaceutical Products Inc, Westborough, Mass).^14-17 Ganciclovir's investigational use began in 1984; it received approval from the Food and Drug Administration in 1989. The only form of ganciclovir approved for use is the intravenous one. The initial, 2-week, high-dose induction therapy is begun to control the . . . [Full Text PDF of this Article]

Author Affiliations

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?